Methods of using variants of FGF19 polypeptides for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-10369199-B2
Application number	US-201415032605-A
Country	US
Kind code	B2
Filing date	Oct 27, 2014
Priority date	Oct 28, 2013
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

Provided are methods of antagonizing the oncogenic activity of FGF19 in a subject. Also provided are methods of treating a FGF19-dependent cancer or tumor, or a symptom thereof in a subject.

First claim

What is claimed is:

1. A method of treating a FGF19-dependent cancer or tumor, or a symptom thereof, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:1, thereby treating the FGF19-dependent cancer or tumor, or symptom thereof in the subject.

2. The method of claim 1 , wherein the FGF19-dependent cancer or tumor is hepatocellular carcinoma, a colon cancer or tumor, a prostate cancer or tumor, or a lung cancer or tumor.

3. The method of claim 2 , wherein polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

4. The method of claim 3 , wherein the FGF19-dependent cancer or tumor is hepatocellular carcinoma.

5. The method of claim 3 , wherein the FGF19-dependent cancer or tumor is a colon cancer or tumor.

6. The method of claim 3 , wherein the FGF19-dependent cancer or tumor is a prostate cancer or tumor.

7. The method of claim 3 , wherein the FGF19-dependent cancer or tumor is a lung cancer or tumor.

8. The method of claim 2 , wherein polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1.

9. The method of claim 8 , wherein the FGF19-dependent cancer or tumor is hepatocellular carcinoma.

10. The method of claim 8 , wherein the FGF19-dependent cancer or tumor is a colon cancer or tumor.

11. The method of claim 8 , wherein the FGF19-dependent cancer or tumor is a prostate cancer or tumor.

12. The method of claim 8 , wherein the FGF19-dependent cancer or tumor is a lung cancer or tumor.

13. The method of claim 1 , wherein polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

14. The method of claim 1 , wherein polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1.

15. A method of antagonizing the oncogenic activity of FGF19 in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:1, thereby antagonizing the oncogenic activity of FGF19 in the subject.

16. The method of claim 15 , wherein polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

17. The method of claim 16 , wherein the subject has hepatocellular carcinoma.

18. The method of claim 16 , wherein the subject has a colon cancer or tumor.

19. The method of claim 16 , wherein the subject has a prostate cancer or tumor.

20. The method of claim 16 , wherein the subject has a lung cancer or tumor.

21. The method of claim 15 , wherein polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1.

22. The method of claim 21 , wherein the subject has hepatocellular carcinoma.

23. The method of claim 21 , wherein the subject has a colon cancer or tumor.

24. The method of claim 21 , wherein the subject has a prostate cancer or tumor.

25. The method of claim 21 , wherein the subject has a lung cancer or tumor.

Assignees

• Ngm Biopharmaceuticals Inc

Inventors

• Ling Lei

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P13/08

  of the prostate · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title